Ibex Wealth Advisors Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ibex Wealth Advisors opened a new position in Thermo Fisher Scientific, buying 6,687 shares worth about $3.9 million in the fourth quarter.
• Thermo Fisher reported strong quarterly results, with EPS of $5.44 and revenue of $11.01 billion, both beating analysts’ estimates. Revenue rose 6.2% year over year, and the company maintained FY2026 EPS guidance of $24.64-$25.12.
• The stock was down 0.2% in Wednesday trading, while analysts remain generally positive with a consensus rating of Moderate Buy and an average price target of $608.95.

Ibex Wealth Advisors acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,687 shares of the medical research company's stock, valued at approximately $3,875,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Howard Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock valued at $1,791,000 after purchasing an additional 16 shares during the period. Petros Family Wealth LLC grew its stake in Thermo Fisher Scientific by 3.9% in the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company's stock worth $264,000 after purchasing an additional 17 shares during the period. Salomon & Ludwin LLC raised its holdings in Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after purchasing an additional 17 shares in the last quarter. Pallas Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 1.5% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company's stock valued at $728,000 after buying an additional 18 shares during the period. Finally, Red Door Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company's stock valued at $1,250,000 after buying an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.2%

NYSE:TMO opened at $472.73 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $175.68 billion, a P/E ratio of 25.99, a P/E/G ratio of 2.10 and a beta of 0.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm has a 50-day simple moving average of $478.34 and a two-hundred day simple moving average of $525.54.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.34%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TMO shares. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Morgan Stanley reiterated an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Finally, Piper Sandler began coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a "neutral" rating and a $510.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $608.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.